Skip to main content
Fig. 6 | Molecular Neurodegeneration

Fig. 6

From: Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders

Fig. 6

Baseline NfL and GFAP/NfL ratio can discern FTLD-tau from FTLD-TDP pathology. a-c Comparisons of baseline GFAP (a), NfL (b), or GFAP/NfL (c) in the combined group of participants with a FTD syndrome with no mutation, or either a C9orf72, GRN, or MAPT mutation. p values are from analysis adjusted for age, sex and symptom duration. p < 0.0083 is considered statistically significant; ****p < 0.0001 (comparison to no mutation participants, “None”); ####p < 0.0001 (comparison to GRN mutation carriers). d-f Comparisons of GFAP (d), NfL (e), or GFAP/NfL (f) between neuropathologically confirmed participants with FTLD-tau or with FTLD-TDP. p values are from analysis adjusted for age at biomarker measurement, sex, symptom duration, and age at death. p < 0.025 is considered statistically significant; ****p < 0.0001. In all panels, the number of participants (n) is shown, and horizontal bars represent median GFAP, NfL or GFAP/NfL concentrations, which are shown on the base 2 logarithm scale. See Tables S27 and S28 for panels (a-c), and Table S29 for panels (d-f)

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326